Protein tyrosine phosphatase inhibitors: A patent review (2002-2011)

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 2, 2012, Pages 125-153

  Sobhia, Masilamani Elizabeth ^a   Paul, Stanly ^a   Shinde, Ranajit ^a   Potluri, Mrudula ^a   Gundam, Venkatesh ^a   Kaur, Amandeep ^a   Haokip, Thongtinlal ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Absorption; Active site and allosteric site inhibitors; Patents; PTPs; Selectivity

Indexed keywords

(ETHYNEDIYL)BIS BENZENE; [BENZYL[2 CYCLOHEXYL 2 [4 (1 NAPHTHYL)PHENYL]ETHYL]AMINO](OXO)ACETIC ACID; AZOLOARIN DERIVATIVE; CYCLIC ALABENZIMIDAZOLE; CYCLO PROPYLPHENYL PHENYLOXAMIDE; OXINDOLE; PHOSPHONIC ACID BIARYL DERIVATIVE; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE NON RECEPTOR 22; PYRAZINE; PYRIDOPYRIMIDINE; QUINOLYL; STIBOGLUCONATE SODIUM; TRIAZOLOPYRIDINE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALLERGIC DISEASE; ALZHEIMER DISEASE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; AUTOIMMUNE HEPATITIS; DIABETES MELLITUS; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; GLUCOSE INTOLERANCE; HUMAN; INFECTION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LEISHMANIASIS; LEUKEMIA; MALIGNANT TRANSFORMATION; METABOLIC SYNDROME X; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SALMONELLOSIS; SOLID TUMOR; SYSTEMIC LUPUS ERYTHEMATOSUS; YERSINIA INFECTION;

ANIMALS; BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; LEGISLATION, DRUG; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; PATENTS AS TOPIC; PROTEIN CONFORMATION; PROTEIN TYROSINE PHOSPHATASES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84857578416     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.661414     Document Type: Review

References (107)

1. Alonso A, Sasin J, Bottini N, et al. Protein tyrosine phosphatases in the human genome. Cell 2004;117:699-711
2. Stone RL, Dixon JE. Protein-tyrosine phosphatases. J Biol Chem 1994;269:31323-6
3. Fauman EB, Saper MA. Structure and function of the protein tyrosine phosphatases. Trends Biochem Sci 1996;21:413-17
4. Zhang ZY. Protein tyrosine phosphatases: prospects for therapeutics. Curr Opin Chem Biol 2001;5:416-23
5. Tautz L, Pellecchia M, Mustelin T. Targeting the PTPome in human disease. Expert Opinion On Therapeutic Targets 2006; 10:157-77
6. Neel BG, Tonks NK. Protein tyrosine phosphatases in signal transduction. Curr Opin Cell Biol 1997;9:193-204
7. Chan AC, Desai DM, Weiss A. The role of protein tyrosine kinases and protein tyrosine phosphatases in T cell antigen receptor signal transduction. Annu Rev Immunol 1994;12:555-92
8. Li L, Dixon JE. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. Seminars in Immunology 2000;12:75-84
9. Sun H, Tonks NK. The coordinated action of protein tyrosine phosphatases and kinases in cell signaling. Trends Biochem Sci 1994;19:480-5
10. Gebbink MF, Zondag GC, Wubbolts RW, et al. Cell-cell adhesion mediated by a receptor-like protein tyrosine phosphatase. J Biol Chem 1993;268:16101
11. Stoker AW. Protein tyrosine phosphatases and signalling. J Endocrinol 2005;185:19
12. Cheng A, Dube N, Gu F, et al. Coordinated action of protein tyrosine phosphatases in insulin signal transduction. Eur J Biochem 2002;269:1050-9
13. Galic S, Hauser C, Kahn BB, et al. Coordinated regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP. Mol Cell Biol 2005;25:819
14. Wang WQ, Sun JP, Zhang ZY. An overview of the protein tyrosine phosphatase superfamily. Curr Top Med Chem 2003;3:739-48
15. Tonks NK, Neel BG. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol 2001;13:182-95
16. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006;7:833-46
17. Fischer EH, Charbonneau H, Tonks NK. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. Science 1991;253:401
18. Kim HO, Blaskovich MA. Recent discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin Ther Patent 2002;12:871-905
19. Zhang ZY. Protein-tyrosine phosphatases: biological function, structural characteristics, and mechanism of catalysis. Crit Rev Biochem Mol Biol 1998;33:1-52
20. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 1995;9:576
21. Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912
22. Shultz LD, Rajan TV, Greiner DL. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol 1997;15:302-7
23. Zhang ZY. Mechanistic studies on protein tyrosine phosphatases. Prog Nucleic Acid Res Mol Biol 2003;73:171-220
24. Brady-Kalnay SM, Rimm DL, Tonks NK. Receptor protein tyrosine phosphatase PTPmu associates with cadherins and catenins in vivo. J Cell Biol 1995;130:977
25. Yuvaniyama J, Denu JM, Dixon JE, et al. Crystal structure of the dual specificity protein phosphatase VHR. Science 1996;272:1328-31
26. Kerk D, Bulgrien J, Smith DW, et al. The complement of protein phosphatase catalytic subunits encoded in the genome of Arabidopsis. Plant Physiol 2002;129:908
27. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 2008;27:253-61
28. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J 2000;14:6
29. Zhang ZY, Palfey BA, Wu L, et al. Catalytic function of the conserved hydroxyl group in the protein tyrosine phosphatase signature motif. Biochemistry 1995;34:16389-96
30. Yaffe MB. Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol 2002;3:177-86
31. Sheriff S, Beno BR, Zhai W, et al. Small molecule Receptor Protein Tyrosine Phosphatase (RPTP) ligands that inhibit phosphatase activity via perturbation of the tryptophan-proline-aspartate (WPD) loop. J Med Chem 2011;54:6548-62
32. Taylor SD. Inhibitors of protein tyrosine phosphatase 1B (PTP1B). Curr Top Med Chem 2003;3:759-82
33. Johnson TO, Ermolieff J, Jirousek MR. Protein tyrosine phosphatase 1B inhibitors for diabetes. Nat Rev Drug Discov 2002;1:696-709
34. Pedersen AK, Guo XL, Moller KB, et al. Residue 182 influences the second step of protein-tyrosine phosphatase-mediated catalysis. Biochem J 2004;378:421-33
35. Madhurantakam C, Rajakumara E, Mazumdar PA, et al. Crystal structure of low-molecular-weight protein tyrosine phosphatase from Mycobacterium tuberculosis at 1.9-A resolution. J Bacteriol 2005;187:2175
36. Tabernero L, Aricescu AR, Jones EY, et al. Protein tyrosine phosphatases: structure-function relationships. FEBS J 2008;275:867-82
37. Denu JM, Dixon JE. Protein tyrosine phosphatases: mechanisms of catalysis and regulation. Curr Opin Chem Biol 1998;2:633-41
38. Barr AJ, Ugochukwu E, Lee WH, et al. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 2009;136:352-63
39. Ren l, Chen X, Luechapanichkul R, et al. Substrate specificity of protein tyrosine phosphatases 1B, RPTP, SHP-1, and SHP-2. Biochemistry 2011;50(12):2339-56
40. Zhang ZY. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol 2002;42:209-34
41. Zhang S, Zhang ZY. PTP1B as a drug target: recent developments in PTP1B inhibitor discovery. Drug Discov Today 2007;12:373-81
42. Montalibet J, Kennedy BP. Therapeutic strategies for targeting PTP1B in diabetes. Drug Discov Today 2005;2:129-35
43. Barr AJ. Protein tyrosine phosphatases as drug targets: strategies and challenges of inhibitor development. Future 2010;2:1563-76
44. Liwu Li, Dixon JE. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. Semin Immunol 2010;12(1):75-84
45. Hendriks WJAJ, Elson A, Harroch S, et al. Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. FEBS J 2008;275:816-30
46. Pulido R, Huijsduijnen RH. Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. FEBS J 2008;275:848-66
47. Jiang Y, Chan JLK, Zong CS, et al. Effect of tyrosine mutations on the kinase activity and transforming potential of an oncogenic human insulin-like growth factor I receptor. J Biol Chem 1996;271:160
48. Byon JCH, Kusari AB, Kusari J. Protein-tyrosine phosphatase-1B acts as a negative regulator of insulin signal transduction. Mol Cell Biochem 1998;182:101-8
49. Shoelson SE. SH2 and PTB domain interactions in tyrosine kinase signal transduction. Curr Opin Chem Biol 1997;1:227-34
50. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006;6:307-20
51. Sallee JL, Wittchen ES, Burridge K. Regulation of cell adhesion by protein-tyrosine phosphatases. J Biol Chem 2006;281:16189
52. Ventura JJ, Nebreda AR. Protein kinases and phosphatases as therapeutic targets in cancer. Clin Transl Oncol 2006;8:153-60
53. Hait WN. Targeted cancer therapeutics. Cancer Res 2009;69:1263
54. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 2008;27:179-92
55. Boyce BF, Yao Z, Xing L. Osteoclasts have multiple roles in bone in addition to bone resorption. Crit Rev Eukaryot Gene Expr 2009;19:171
56. Trowbridge IS, Thomas ML. CD45: an emerging role as a protein tyrosine phosphatase required for lymphocyte activation and development. Annu Rev Immunol 1994;12:85-116
57. Mustelin T. Are other protein tyrosine phosphatases than PTPN22 associated with autoimmunity? Semin Immunol 2006;18:254-60
58. Jacobsen M, Schweer D, Ziegler A, et al. A point mutation in PTPRC is associated with the development of multiple sclerosis. Nat Genet 2000;26:495-9
59. Vogel A, Strassburg CP, Manns MP. 77 C/G mutation in the tyrosine phosphatase CD45 gene and autoimmune hepatitis: evidence for a genetic link. Genes Immun 2003;4:79-81
60. Tchilian EZ. Altered CD45 expression and disease. Trends Immunol 2006;27:146-53
61. Siminovitch KA. PTPN22 and autoimmune disease. Nat Genet 2004;36:1248-9
62. Gregersen PK. Gaining insight into PTPN22 and autoimmunity. Nat Genet 2005;37:1300-2
63. Vang T, Miletic AV, Bottini N, et al. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 2007;40:453-61
64. Bottini N, Vang T, Cucca F, et al. Role of PTPN22 in type 1 diabetes and other autoimmune diseases. Semin Immunol 2006;18:207-13
65. Bialy L, Waldmann H. Inhibitors of protein tyrosine phosphatases: next generation drugs? Angew Chem Int Ed 2005;44:3814-39
66. Na MK, Kim KA, Oh H, et al. Protein tyrosine phosphatase 1B inhibitory activity of amentoflavone and its cellular effect on tyrosine phosphorylation of insulin receptors. Biol Pharm Bull 2007;30:379-81
67. Vintonyak VV, Antonchick AP, Rauh D, et al. The therapeutic potential of phosphatase inhibitors. Curr Opin Chem Biol 2009;13:272-83
68. Heneberg P. Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr Med Chem 2009;16(6):706-33
69. Scott LM, Lawrence HR, Sebti SM, et al. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des 2010;16(16):1843-62
70. Vintonyak VV, Waldmann H, Rauh D. Using small molecules to target proteinphosphatases. Bioorg Med Chem 2011;2145-55
71. Kumar R, Shinde RN, Ajay D, Sobhia ME. Probing interaction requirements in PTP1B inhibitors: a comparative molecular dynamics study. J Chem Inf Model 2010;50(6):1147-58
72. Kamerlin SCL, Rucker R, Boresch S. A molecular dynamics study of WPD-loop flexibility in PTP1B. Biochem Biophys Res Commun 2007;356:1011-16
73. Kamerlin SCL, Rucker R, Boresch S. A targeted molecular dynamics study of WPD loop movement in PTP1B. Biochem Biophys Res Commun 2006;345:1161-6
74. Bharatham K, Bharatham N, Kwon YJ, et al. Molecular dynamics simulation study of PTP1B with allosteric inhibitor and its application in receptor based pharmacophore modeling. J Comput Aided Mol Des 2008;22:925-33
75. Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol 2001;167:3391
76. Available from: http://clinicaltrials.gov/ ct2/show/study/NCT01009502
77. Luo L, He X-P, Shen Q, et al. Synthesis of (Glycopyranosyl-triazolyl)- purines and their inhibitory activities against Protein Tyrosine Phosphatase 1B (PTP1B). Chem Biodivers 2011;8:2035-44
78. Song Z, He XP, Li C, et al. Preparation of triazole-linked glycosylated I ±-ketocarboxylic acid derivatives as new PTP1B inhibitors. Carbohydr Res 2011;346:140-5
79. Yang JW, He XP, Li C, et al. A unique and rapid approach toward the efficient development of novel protein tyrosine phosphatase (PTP) inhibitors based on clicked' pseudo-glycopeptides. Bioorg Med Chem Lett 2011;21:1092-6
80. Merck and Co., Inc. Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase-1B (PTP1B). US0052346; 2002
81. Abbott Laboratories. Protein tyrosine phosphatase inhibitors. US0077347; 2002
82. Abbott Laboratories. Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors. US0035137; 2002
83. Merck Erosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphate. US6583126; 2003
84. Abbott Laboratories. Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors. US6627767; 2003
85. Amster,Rothstein & Ebenstein. Ptb1b inhibitors and ligands. US20040191926; 2004
86. Nixon & Vanderhye. Novel tyrosine phosphatase inhibitor. US0138218; 2004
87. Calfee Halter & Griswold LLP. Inhibition of protein tyrosine phosphatases and SH2 domains by a neutral phosphotyrosine mimetic(py). US0009956; 2004
88. Abbott Laboratories. Selective protein tyrosine phosphatatase inhibitors. US6972340; 2005
89. Wyeth. Phenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia. US6844358; 2005
90. Transtech Pharma. Bis-heteroaryl alkanes as therapeutic agents. US0128784; 2006
91. Kilpatrick Stockton. Substituted imidazole derivatives compositions and methods of use as PTPase inhibitors. US0191385; 2007
92. Hoffmann-La Roche, Inc. Pyridopyrimidine protein tyrosine phosphatase inhibitors. US0021445; 2007
93. Sanofi-Aventis U.S. LLC. Diphenylamine-substituted salicylthiazole derivatives and related compounds as phosphotyrosine phosphatase-1B (PTP- 1B) inhibitors for using as blood sugar decreasing active ingredients for treating diabetes. US0191441; 2007
94. Abbott Laboratories. Protein-tyrosine phosphatase inhibitors and uses thereof. US7169797; 2007
95. Shanghai Institute of Materia Medica Chinese Academy of Sciences. Protein tyrosine phosphatase-1B inhibitor, preparation methods and uses thereof. US0004325; 2008
96. Institute of Pharmaceutical Discovery LLC. Heterocyclic substituted carboxylic acids. US0146574; 2008
97. Hoffmann-La Roche, Inc. Quinazoline protein tyrosine phosphatase inhibitors. US0105477; 2009
98. Shanghai Institute Of Materia Medica Chinese Academy of Sciences. Protein tyrosine hosphatase 1b inhibitor, preparation methods and uses thereof. EP2133342; 2009
99. Hoffmann-La Roche, Inc. Pyridopyrimidine protein tyrosine phosphatase inhibitors. US0062276; 2009
100. Merck and Co., Inc. Fused aromatic ptp-1b inhibitors. US0022477; 2010
101. Laboratoires Serono SA. Oxindole hydrazine modulators of protein tyrosine phosphatases (PTPs). US007696231; 2010
102. Merck Serono SA. 1,1'-(1,2-Ethynediyl) bis-benzene derivatives as PTP-1B inhibitors. US7947851; 2011
103. Wiesmann C, Barr KJ, Kung J, et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 2004;11:730-7
104. Elchebly M, Payette P, Michaliszyn E, et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 1999;283:1544
105. Wrobel J, Sredy J, Moxham C, et al. PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo [b] naphtho [2, 3-d] furans and 11-arylbenzo [b] naphtha [2, 3-d] thiophenes. J Med Chem 1999;42:3199-202
106. Huang P, Ramphal J, Wei J, et al. Structure-based design and discovery ofnovel inhibitors of protein tyrosine phosphatases. Bioorg Med Chem 2003;11:1835-49
107. Taylor SD, Hill B. Recent advances in protein tyrosine phosphatase 1B inhibitors. Expert Opin Investig Drugs 2004;13:199-214